Final Days to Submit Abstracts for the 2025 Lysosomal Disease Summit in Sydney, Australia
Researchers Invited to Contribute to APAC's Leading Lysosomal Disease Meeting
'This year's Summit will bring together pioneering minds to explore cutting-edge research and ignite collaborations that shape the future of lysosomal diseases.'— Professor Maria Fuller, BAppSc, MAppSc, PhD, FFSc(RCPA)
SYDNEY, NSW, AUSTRALIA, May 4, 2025 / EINPresswire.com / -- The 3rd Annual Lysosomal Disease Summit, to be held 24–26 October 2025 at the Hyatt Regency Sydney, invites researchers, clinicians, and industry partners to participate in this premier scientific meeting focused on advancing lysosomal disease research, diagnostics, and care across the Asia-Pacific region.
The Call for Abstracts remains open through 9 May 2025, offering a critical opportunity for professionals in the lysosomal disease field to contribute to the Summit's scientific programme. Accepted abstracts will be considered for oral or poster presentations, with select oral presenters receiving a discounted registration rate. A limited number of scholarships are also available to support participation.
'Innovation begins with connection,' said Professor Maria Fuller, BAppSc, MAppSc, PhD, FFSc(RCPA), a 2025 Lysosomal Disease Summit Course Director. 'This year's Summit will bring together pioneering minds to explore cutting-edge research and ignite collaborations that shape the future of lysosomal diseases. Every contribution helps drive discovery forward and creates opportunities to meaningfully improve patient care.'
Programme Highlights
• Groundbreaking research presentations from international and APAC-based experts
• Strategic panel discussions on current challenges and treatment developments
• Dedicated sessions to support early-career researchers
• Networking and collaboration opportunities with global and regional stakeholders
Attendees will engage with leading voices in lysosomal disease research and treatment, explore diagnostic innovations, and build new partnerships across industry, academia, and clinical care.
For full details on abstract submissions, registration, sponsorship, and Summit updates, visit lysosomaldiseasesummit.org.
About the Lysosomal Disease Summit
The Lysosomal Disease Summit, a collaborative effort with Fabry Australia and independently managed by Etherio, is a premier scientific event dedicated to advancing research, collaboration, and innovation in lysosomal disease treatment. Now in its third year, the Summit serves as a vital forum for experts across the APAC region to share knowledge and drive progress in the field.
Sarah Jansen
Etherio
email us here
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
UnitedHealth Group received multiple bids for Latin American operations
-- UnitedHealth Group (NYSE:UNH) is considering several offers for its Latin American operations, according to a Reuters report on Monday. The move comes as the largest U.S. health insurer faces challenges that include the departure of its CEO and an alleged criminal accounting investigation. The insurer has been attempting to leave Latin America since 2022, with the sale of its Banmedica subsidiary becoming more urgent in recent months due to increasing pressures on multiple fronts, the report said. So far, UnitedHealth has reportedly received four preliminary bids for Banmedica, which operates in Colombia and Chile, with an estimated value of about $1 billion. In May, UnitedHealth's shares dropped 25.5%, and the year-to-date decline stands at 40%. The company withdrew from Brazil in 2023 and from Peru in March 2025. It aims to secure around $1 billion for Banmedica's operations in Colombia and Chile. The company anticipates setting a deadline for final proposals as early as July. The bids reportedly include offers from Washington, D.C.-based private equity firm Acon Investments, Sao Paulo-based private equity firm Patria Investments, Texas non-profit health organization Christus Health, and Lima-based healthcare and insurance provider Auna. The report mentioned that Auna is currently in discussions with a financial partner. Related articles UnitedHealth Group received multiple bids for Latin American operations Tesla shares slip after double downgrade amid Trump feud fallout What are the three big things in markets now? RBC weighs in
Yahoo
an hour ago
- Yahoo
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information Please contact: Media: Lakshmi Ramakrishna lramakrishna@ Investor & Partnership: Ramkesh Meena bd@
Yahoo
2 hours ago
- Yahoo
UMMC expands health care access with UMMC Madison
CANTON, Miss. (WJTV) – The University of Mississippi Medical Center (UMMC) acquired Merit Health Madison, which now operates as UMMC Madison. With 67 licensed beds, officials said the Canton-based hospital will expand UMMC's mission to deliver high-quality, accessible care to more Mississippians while providing additional training opportunities for future health care providers. Lyme-disease isn't the only tick-borne threat. Doctors warn these other diseases are spreading 'As Mississippi's only academic medical center, we must continue to be focused on our three-part mission to educate the next generation of health care providers, conduct impactful research and deliver accessible high-quality health care,' said Dr. LouAnn Woodward, vice chancellor of health affairs. 'Every decision we make is rooted in our mission.' The acquisition was finalized May 1. As the full owner, UMMC will integrate the facility more closely into its academic and health care system. UMMC Madison will continue to provide a wide range of community hospital services, including emergency services, medical-surgical care, ICU, pulmonology, pathology, cardiology, radiology, neurology, nephrology, general surgery and GI services. The hospital will operate as a community hospital. UMMC Madison will also become a training site for medical students, residents and fellows, who will have the opportunity to learn at a community hospital. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
